The New York Times
By RONI CARYN RABIN
Published: February 24, 2010
Women older than 40 are unlikely to get much benefit from the vaccine for the virus that causes cervical cancer, a new study reports.
The vaccine for human papillomavirus, or HPV, is recommended for women up to age 26 and girls as young as 9. To determine whether older women might be protected as well, the new study looked at patterns of HPV infection as women age, said Dr. Ana Cecilia Rodríguez,...
One of the HPV vaccines available in Canada has now been approved for use by boys and men.
Merck announced Tuesday that Health Canada has approved its vaccine Gardasil for use in boys and men aged nine through 26.
The vaccine is designed to prevent infection from the HPV strains that can cause genital warts (types 6 and 11). It can also protect against HPV types 16 and 18 which, when sexually transmitted...
Top Doctors to Present Results of FDA Clinical Trial of Guided Therapeutics’ Cervical Cancer Detection Technology at Scientific Meeting
Business Wire
February 23, 2010 08:45 AM Eastern Time
Five Presentations Scheduled for American Society for Colposcopy and Cervical Pathology Meeting
NORCROSS, Ga.--(BUSINESS WIRE)--Results of the U.S. Food and Drug Administration (FDA) pivotal clinical trial for the Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP)...
Vaccine demonstrates high efficacy against HPV types 16 and 18 in 18-25 year old women
New data presented this week at the EUROGIN conference support that young adult women, a population group not typically targeted for cervical cancer immunization, could benefit from the vaccine.
The primary focus of most current recommendations is to vaccinate young girls before the onset of sexual...
Preliminary Data from Roche ATHENA Cervical Cancer Trial Support Value of Human Papillomavirus Genotyping
MONTE CARLO, Monaco, Feb. 18 /PRNewswire-FirstCall/ -- Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today that preliminary data from its ATHENA (Addressing THE Need for Advanced HPV Diagnostics) trial support the importance of screening for human papillomavirus (HPV) genotypes that put women at highest risk for developing cervical cancer. ATHENA is a prospective,...
